NCT01853982

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam With That of Piperacillin/Tazobactam in Ventilator Associated Pneumonia

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (IV) ceftolozane/tazobactam with that of IV piperacillin/tazobactam in the treatment of ventilator-associated pneumonia (VAP) in adult participants .

Conditions

• Ventilator-Associated Pneumonia (VAP)

Interventions

Type	Name	Description
DRUG	Ceftolozane/Tazobactam
DRUG	Piperacillin/Tazobactam

Timeline

• Start date: 2013-06-14
• Primary completion: 2013-11-20
• Completion: 2013-12-08
• First posted: 2013-05-15
• Last updated: 2018-11-16
• Results posted: 2015-06-15

Locations

19 sites across 3 countries: United States, Australia, New Zealand